

10/568963

IAP20 Rec'd PCT/PTO 21 FEB 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Hiroyuki KAI et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2006_0206A
Filed February 21, 2006 :
2-NAPHTHYLIMINO-1,3-THIAZINE
DERIVATIVE
[Corresponding to PCT/JP2004/012086
Filed August 24, 2004]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☒ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application
PCT/JP2004/012086; and/or
- ☐ each reference previously cited in prior parent application Serial No.
_____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the
above-entitled application, **or**

ATTACHMENT C }

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

10/568963


1AP20 Rec'd FCT/PTO 21 FEB 2006

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
- a. ☐ a full or partial English language translation submitted herewith,
 - b. ☒ a foreign patent office (International) search report (in the English language) submitted herewith (Attachment F),
 - c. ☒ the concise explanation contained in the specification of the present application at page 2,
 - d. ☒ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:
5. ☐ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Hiroyuki KAI et al.

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

By 
Matthew M. Jacob
Registration No. 25,154
Attorney for Applicants

MJ/kes
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
February 21, 2006

Sheet 1 of 1		INFORMATION DISCLOSURE STATEMENT					
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: February 21, 2006				ATTY DOCKET NO. 2006_0206A		SERIAL NO NEW 10/568963	
				APPLICANT Hiroyuki KAI et al.			
				FILING DATE February 21, 2006		GROUP	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	6,916,806	07/2005	Kai et al.			
	AB	6,818,640	11/2004	Hanasaki et al.			
	AC	2005/0101590	05/2005	Yasui et al.			
	AD	6,017,919	01/2000	Inaba et al.			
	AE	5,948,777	09/1999	Bender et al.			
	AF	6,509,352	01/2003	Inaba et al.			
	AG	2004/0082619	04/2004	Tada et al.			
	AH	2005/0009902	01/2005	Miyaji et al.			
	AI						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	99/02499	01/1999	WO			abstract
	AK	02/72562 A1	09/2002	WO			abstract
	AL	01/19807 A1	03/2001	WO			abstract
	AM	03/70277 A1	03/2003	WO			abstract
	AN	03/35109 A1	05/2003	WO			abstract
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AO	Fride, Ester, "Cannabinoids and Cystic Fibrosis: A Novel Approach to Etiology and Therapy", <i>Journal of Cannabis Therapeutics</i> , Vol. 2(1), pp. 59 to 71 (2002).					
	AP	Lake, K. et al., "Cardiovascular Effects of Anandamide in Anesthetized and Conscious Normotensive and Hypertensive Rats", <i>Hypertension</i> , Vol. 29, No. 5, pp. 1204 to 1211 (1997).					
	AQ	Munro, S. et al., "Molecular characterization of a peripheral receptor for cannabinoids" <i>Nature</i> , Vol. 365, pp. 61 to 65 (1993).					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include cop. this form with next communication to applicant.